Perimenopause Irregular Periods and Abnormal Bleeding Guide

Perimenopause Irregular Periods and Abnormal Bleeding: A Comprehensive Guide

Up to one-third of women will experience abnormal uterine bleeding (AUB) in their lifetime, with perimenopause being one of the most common times for these irregularities to appear. This period, which precedes the final menstrual period, is characterized by profound hormonal fluctuations that directly disrupt the menstrual cycle’s rhythm and flow. Understanding the definitions, causes, and evidence-based management strategies for AUB can empower women navigating this transition.

The PALM-COEIN Framework: A Diagnostic Map for Irregular Bleeding

According to the StatPearls article by Mikes, Vadakekut, and Sparzak, the International Federation of Obstetrics and Gynecology (FIGO) developed the PALM-COEIN system to standardize the diagnosis of AUB. This framework separates potential causes into structural (PALM) and nonstructural (COEIN) groups. The structural “PALM” causes include Polyps, Adenomyosis, Leiomyoma (fibroids), and Malignancy/hyperplasia. These can be visualized or confirmed through imaging or biopsy. The nonstructural “COEIN” causes are Coagulopathy, Ovulatory dysfunction, Endometrial disorders, Iatrogenic (medication-related), and Not otherwise classified. For perimenopausal women, the “O” for ovulatory dysfunction is frequently the central issue, as the body’s normal ovulation mechanism becomes irregular. However, it is essential to remember that perimenopausal women can also have coexisting structural issues like fibroids, making a thorough evaluation necessary. The PALM-COEIN system provides clinicians with a structured method to investigate all possibilities.

Progesterone Deficiency as the Central Mechanism

The research by Jewson, Purohit, and Lumsden explains the specific hormonal mechanism behind perimenopausal AUB. In a normal cycle, ovulation triggers the production of progesterone, which stabilizes and matures the uterine lining (endometrium). During perimenopause, ovulation becomes sporadic. Cycles may occur where an egg is not released—this is an anovulatory cycle. Without ovulation, no progesterone is produced. Estrogen, however, may continue to be secreted erratically. This unopposed estrogen stimulates the endometrium to grow thick and unstable without the stabilizing effect of progesterone. The result is irregular, unpredictable, and often heavy or prolonged bleeding as the overgrown lining sheds incompletely. This imbalance directly links the hormonal chaos of perimenopause to the practical problem of disruptive bleeding.

Evaluation: Ruling Out Other Causes in a High-Risk Group

While ovulatory dysfunction is common, the evaluation for AUB in perimenopause must be comprehensive. The StatPearls resource details that assessment begins with a detailed history tracking the cycle’s frequency, regularity, duration, and volume. A physical exam follows. Laboratory tests often check for anemia, thyroid disorders, and clotting issues. Because the risk of endometrial hyperplasia and cancer increases with age and unopposed estrogen exposure, further investigation is frequently warranted. Transvaginal ultrasound measures endometrial thickness, and an endometrial biopsy may be performed to sample the tissue directly. This step is particularly important to rule out pathology before attributing all bleeding solely to perimenopausal hormone shifts. It ensures that other treatable or serious conditions within the PALM-COEIN spectrum are not missed.

Treatment Strategies: From Progesterone to Procedures

Management of AUB in perimenopause, as outlined in both sources, is tailored to the diagnosed cause, symptom severity, and the patient’s health goals. For ovulatory dysfunction, the cornerstone of treatment is often progesterone or progestin therapy. This can be administered cyclically (e.g., for 10-14 days each month) to induce a regular, controlled withdrawal bleed, or continuously to stop bleeding altogether and achieve amenorrhea. Options include oral pills, the levonorgestrel-releasing intrauterine system (IUS), or other progestin-only methods. For heavy bleeding, tranexamic acid, an anti-fibrinolytic, can reduce blood loss. Non-hormonal options like nonsteroidal anti-inflammatory drugs (NSAIDs) may also help with cramping and flow. If structural causes like large fibroids or polyps are identified, surgical options such as hysteroscopic resection may be considered. For women who have completed their families and suffer from severe, refractory bleeding, definitive surgical management like endometrial ablation or hysterectomy may be discussed. The choice depends heavily on individual circumstances and preferences.

Perimenopausal irregular bleeding, while common, should not be dismissed as merely a nuisance. It is a clear signal of the hormonal transition and, at times, a symptom of other conditions. The FIGO PALM-COEIN system offers a clear diagnostic pathway, while an understanding of the progesterone-estrogen imbalance provides insight into the core mechanism. A thorough evaluation followed by personalized treatment—often starting with progesterone therapy—can effectively manage symptoms, protect long-term health, and significantly improve quality of life during the menopausal transition.

Sources:
https://pubmed.ncbi.nlm.nih.gov/30422508/
https://pubmed.ncbi.nlm.nih.gov/32698992/